Parisian drug developer Gensight Biologics is swinging for a $100 million U.S. IPO to fund its work on potential one-time treatments for serious retinal diseases, angling to take advantage of a bullish market for biotechs.

…read more

Source: Gensight scouts a $100M IPO for its ocular gene therapies


0 No comments